- South Korean pharmaceutical companies have joined the rat race to develop vaccines and treatments for the novel coronavirus, and several of them have received the nod for clinical trials from the country's drug safety agency.
- Among the front-runners is Celltrion Inc.'s antiviral antibody treatment candidate called CT-P59 that is currently in the process of phase two and three trials both at home and abroad.
Tags : Celltrion Inc., AstraZeneca, Phase 3 Trials, Bioneer Corp., CT-P59, COVID-19, coronavirus, epidemic,
comments (0)